請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/8666
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 余家利 | |
dc.contributor.author | Ming-Chi Lu | en |
dc.contributor.author | 呂明錡 | zh_TW |
dc.date.accessioned | 2021-05-20T19:59:30Z | - |
dc.date.available | 2013-09-09 | |
dc.date.available | 2021-05-20T19:59:30Z | - |
dc.date.copyright | 2010-09-09 | |
dc.date.issued | 2010 | |
dc.date.submitted | 2010-06-05 | |
dc.identifier.citation | 1. Alenius GM, Berglin E, and Rantapää Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann. Rheum. Dis. 2006, Mar;65(3):398-400.
2. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315-24. 3. Atzeni F, Sarzi-Puttini P, Lama N, Bonacci E, Bobbio-Pallavicini F, Montecucco C, and Caporali R. Anti-cyclic citrullinated peptide antibodies in primary Sjogren syndrome may be associated with non-erosive synovitis. Arthritis Res. Ther. 2008 May;10(3):R51. 4. Auger I, Sebbag M, Vincent C, Balandraud N, Guis S, Nogueira L, Svensson B, Cantagrel A, Serre G., and Roudier J. Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum. 2005 Nov;52(11):3424-32. 5. Baeten D, Peene I, Union A, Meheus L, Sebbag M, Serre G., Veys EM, and De Keyser F. Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies. Arthritis Rheum. 2001 Oct;44(10):2255-62. 6. Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, Gibbons L, Plant D, Wilson AG, Marinou I, Morgan A, Emery P, YEAR consortium, Steer S, Hocking L, Reid DM, Wordsworth P, Harrison P, and Worthington J. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Hum. Mol. Genet. 2008 Aug 1;17(15):2274-9. 7. Berglin E, Padyukov L, Sundin U, Hallmans G., Stenlund H, Van Venrooij WJ, Klareskog L, and Dahlqvist SR. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res. Ther. 2004;6(4):R303-8. 8. Bingham CO 3rd. Emerging therapeutics for rheumatoid arthritis. Bull. NYU. Hosp. Jt. Dis. 2008;66(3):210-5. 9. Bläss S, Haferkamp C, Specker C, Schwochau M, Schneider M, and Schneider EM. Rheumatoid arthritis: autoreactive T cells recognising a novel 68k autoantigen. Ann. Rheum. Dis. 1997 May;56(5):317-22. 10. Bläss S, Specker C, Lakomek HJ, Schneider EM, and Schwochau M. Novel 68 kDa autoantigen detected by rheumatoid arthritis specific antibodies. Ann. Rheum. Dis. 1995 May;54(5):355-60. 11. Bläss S, Union A, Raymackers J, Schumann F, Ungethüm U, Müller-Steinbach S, De Keyser F, Engel JM, and Burmester GR. The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum. 2001 Apr;44(4):761-71. 12. Bodman-Smith MD, Corrigall VM, Berglin E, Cornell HR, Tzioufas AG, Mavragani CP, Chan C, Rantapää-Dahlqvist S, and Panayi GS. Antibody response to the human stress protein BiP in rheumatoid arthritis. Rheumatology. (Oxford) 2004 Oct;43(10):1283-7. 13. Bombardieri M, Alessandri C, Labbadia G, Iannuccelli C, Carlucci F, Riccieri V, Paoletti V, Valesini G. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther. 2004;6(2):R137-41. 14. Brennan FM. and McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J. Clin. Invest 2008 Nov;118(11):3537-45. 15. Brownlie RJ, Myers LK, Wooley PH, Corrigall VM, Bodman-Smith MD, Panayi GS, and Thompson SJ. Treatment of murine collagen-induced arthritis by the stress protein BiP via interleukin-4-producing regulatory T cells: a novel function for an ancient protein. Arthritis Rheum. 2006 Mar;54(3):854-63. 16. Bugatti S, Codullo V, Caporali R, and Montecucco C. B cells in rheumatoid arthritis. Autoimmun. Rev. 2007 Dec;7(2):137-42. 17. Campanella ME, Chu H, Wandersee NJ, Peters LL, Mohandas N, Gilligan DM, and Low PS. Characterization of glycolytic enzyme interactions with murine erythrocyte membranes in wild-type and membrane protein knockout mice. Blood 2008 Nov 1;112(9):3900-6. 18. Cao D, van Vollenhoven R, Klareskog L, Trollmo C, and Malmstrom V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res. Ther. 2004;6(4):R335-46. 19. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, and Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 1975 Sep;72(9):3666-70 20. Chan MT, Owen P, Dunphy J, Cox B, Carmichael C, Korendowych E, and McHugh NJ. Associations of erosive arthritis with anti-cyclic citrullinated peptide antibodies and MHC Class II alleles in systemic lupus erythematosus. J. Rheumatol. 2008 Jan;35(1):77-83. 21. Chang J. and Girgis L. Clinical use of anti-TNF-alpha biological agents--a guide for GPs. Aust. Fam. Physician 2007 Dec;36(12):1035-8. 22. Chang X, Yamada R, Suzuki A, Sawada T, Yoshino S, Tokuhiro S, and Yamamoto K. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology. (Oxford) 2005 Jan;44(1):40-50. 23. Chen HA, Lin KC, Chen CH, Liao HT, Wang HP, Chang HN, Tsai CY, and Chou CT. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2006 Jan;65(1):35-9. 24. Cho ML, Yoon CH, Hwang SY, Park MK, Min SY, Lee SH, Park SH, and Kim HY. Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts. Arthritis Rheum. 2004 Mar;50(3):776-84. 25. Ciesielski CJ, Andreakos E, Foxwell BM, Feldmann M. TNFalpha-induced macrophage chemokine secretion is more dependent on NF-kappaB expression than lipopolysaccharides-induced macrophage chemokine secretion. Eur J Immunol 2002 Jul;32(7):2037-45. 26. Clavel C, Nogueira L, Laurent L, Iobagiu C, Vincent C, Sebbag M, and Serre G. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum. 2008 Mar;58(3):678-88. 27. Corrigall VM, Bodman-Smith MD, Fife MS, Canas B, Myers LK, Wooley P, Soh C, Staines NA, Pappin DJ, Berlo SE, van Eden W, van Der Zee R , Lanchbury JS, and Panayi GS. The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J. Immunol. 2001 Feb 1;166(3):1492-8. 28. Dorner T, Egerer K, Feist E, and Burmester GR. Rheumatoid factor revisited. Curr. Opin. Rheumatol. 2004 May;16(3):246-53. 29. Dudek J, Benedix J, Cappel S, Greiner M, Jalal C, Müllar L, Zimmermann R. Functional and pathologies of BiP and its interaction partners. Cell Mol Life Sci. 2009 May; 66(9): 1556-69. 30. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004 Jun 17;350(25):2572-81 31. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, and Trang L. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J. Rheumatol. 1995 Dec;22(12):2208-13. 32. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, and Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 2004 Aug 2;200(3):277-85. 33. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, and Shaw TM; DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006 May;54(5):1390-400. 34. Fearon WR. The carbamido diacetyl reaction: a test for citrulline. Biochem. J. 1939 Jun;33(6):902-7. 35. Feldmann M, Brennan FM, and Maini RN. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 1996;14:397-440. 36. Finckh A, and Gabay C. At the horizon of innovative therapy in rheumatology: new biologic agents. Curr. Opin. Rheumatol. 2008 May;20(3):269-75. 37. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003 May 15;423(6937):356-61. 38. Firestein GS, Alvaro-Gracia JM, and Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 1990 May 1;144(9):3347-53. 39. Foell D, Wittkowski H, Roth J. Mechanisms of Disease: a ‘DAMP’ view of inflammatory arthritis. Nat Clin Pract Rheumatol. 2007 Jul;3(7):382-90 40. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin JJ, Garrone P, Garcia E, Saeland S, Blanchard D, Gaillard C, Das Mahapatra B, Rouvier E, Golstein P, Banchereau J, and Lebecque S. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 1996 Jun 1;183(6):2593-603. . 41. Franklin EC, Holman HR, Muller-Eberhard HJ, and Kunkel HG.. An unusual protein component of high molecular weight in the serum of certain patients with rheumatoid arthritis. J. Exp. Med. 1957 May 1;105(5):425-38 . 42. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006 Dec;33(12):2398-408. 43. Gebe JA, Novak EJ, Kwok WW, Farr AG, Nepom GT and Buckner JH. T cell selection and differential activation on structurally related HLA-DR4 ligands. J. Immunol. 2001 Sep 15;167(6):3250–6. 44. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent C, Simon M, Senshu T, Masson-Bessière C, Jolivet-Reynaud C, Jolivet M, and Serre G. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J. Immunol. 1999 Jan 1;162(1):585-94. 45. Goëb V, Thomas-L'otellier M, Daveau R, Charlionet R, Fardellone P, Le Loët X, Tron F, Gilbert D, and Vittecoq O. Candidate autoantigens identified by mass spectrometry in early rheumatoid arthritis are chaperones and citrullinated glycolytic enzymes. Arthritis Res. Ther. 2009;11(2):R38. 46. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 1995 Dec;38(12):1762–70. 47. Harauz G and Musse AA. A tale of two citrullines--structural and functional aspects of myelin basic protein deimination in health and disease. Neurochem. Res. 2007 Feb;32(2):137-58. 48. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, and Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J. Immunol. 2003 Jul 15;171(2):538-41. 49. Hitchon CA, Alex P, Erdile LB, Frank MB, Dozmorov I, Tang Y, Wong K, Centola M, and El-Gabalawy HS. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J. Rheumatol. 2004 Dec;31(12): 2336-46. 50. Hu L, Evers S, Lu ZH, Shen Y, and Chen J. Two-dimensional protein database of human pancreas. Electrophoresis 2004 Feb;25(3):512-8. 51. Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, van Venrooij WJ, Metzger AL, Genovese MC, and Robinson WH. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann. Rheum. Dis. 2007 Jun;66(6):712-9 52. Hung HC, Lin CY, Liao YF, Hsu PC, Tsay GJ, Liu GY. The functional haplotype of peptidylarginine deiminase IV (S55G, A82V and A112G) associated with susceptibility to rheumatoid arthritis dominates apoptosis of acute T leukemia Jurkat cells. Apoptosis. 2007 Mar;12(3):475-87. 53. Huizinga TW, Amos CI, van der Helm-van Mil AH, Chen W, van Gaalen FA, Jawaheer D, Schreuder GM, Wener M, Breedveld FC, Ahmad N, Lum RF, de Vries RR, Gregersen PK, Toes RE, and Criswell LA. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005 Nov;52(11):3433-8. 54. Jiang, J., Prasad, K., Lafer, E. M. and Sousa, R. Structural basis on interdomain communication in the Hsc70 chaperone. Mol. Cell. 2005 Nov;20(4):513–24. 55. Kallberg H, Padyukov L, Plenge RM, Ronnelid J, Gregersen PK, van der Helm-van Mil AH, Toes RE, Huizinga TW, Klareskog L, and Alfredsson L. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am. J. Hum. Genet. 2007 May;80(5):867-75. 56. Karr RW, Rodey GE, Lee T, Schwartz BD. Association of HLA-DRw4 with rheumatoid arthritis in black and white patients. Arthritis Rheum. 1980 Nov;23(11):1241-5 57. Kastbom A, Strandberg G, Lindroos A, and Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann. Rheum. Dis. 2004 Sep;63(9):1085-9. 58. Kim KW, Cho ML, Park MK, Yoon CH, Park SH, Lee SH, and Kim HY. Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res. Ther. 2005;7(1):R139-48. 59. Klareskog L, Rönnelid J, Lundberg K, Padyukov L, and Alfredsson L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu. Rev. Immunol. 2008;26:651-75. 60. Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson,C., Grunewald J, Rönnelid J, Harris HE, Ulfgren AK, Rantapää-Dahlqvist S, Eklund A, Padyukov L, and Alfredsson L. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006 Jan;54(1):38-46. 61. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, and Holers VM. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J. Clin Invest 2006 Apr;116(4):961-73. 62. Lee DM and Weinblatt ME. Rheumatoid arthritis. Lancet 2001 Sep;358(9285):903-11. 63. Li Q, Lu Q, Bottero V, Estepa G, Morrison L, Mercurio F, Verma IM. Enhanced NF-kappaB activation and cellular function in macrophages lacking IkappaB kinase 1 (IKK1). Proc Natl Acad Sci USA. 2005 Aug 30;102(35):12425-30. 64. Liu GY, Liao YF, Chang WH, Liu CC, Hsieh MC, Hsu PC, Tsay GJ, Hung HC Overexpression of peptidylarginine deiminase IV features in apoptosis of haematopoietic cells Apoptosis. 2006 Feb;11(2):183-96. 65. Lubberts E, Koenders MI, and van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res. Ther. 2005;7(1):29-37. 66. Lundberg K, Nijenhuis S, Vossenaar ER, Palmblad K, van Venrooij WJ, Klareskog L, Zendman AJ, and Harris HE. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res. Ther. 2005;7(3):R458-67. 67. Makrygiannakis D, Hermansson M, Ulfgren AK, Nicholas AP, Zendman AJ, Eklund A, Grunewald J, Skold CM, Klareskog L, and Catrina AI. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann. Rheum. Dis. 2008 Oct;67(10):1488-92. 68. Mastronardi FG, Wood DD, Mei J, Raijmakers R, Tseveleki V, Dosch HM, Probert L, Casaccia-Bonnefil P, and Moscarello MA. Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. J. Neurosci. 2006 Nov;26(44):11387-96. 69. Mavropoulos JC, Cuchacovich M, Llanos C, Aguillón JC, Gatica H, Pizzo SV, and Gonzalez-Gronow M. Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis. J. Rheumatol. 2005 Nov;32(11):2116-24. 70. May MJ and Ghosh S. Signal transduction through NF-kappa B. Immunol. Today 1998 Feb;19(2):80-8. 71. Méchin MC, Sebbag M, Arnaud J, Nachat R, Foulquier C, Adoue V, Coudane F, Duplan H, Schmitt AM, Chavanas S, Guerrin M, Serre G, and Simon M. Update on peptidylarginine deiminases and deimination in skin physiology and severe human diseases. Int. J. Cosmet. Sci. 2007 Jun;29(3):147-68. 72. Mewar D and Wilson AG. Autoantibodies in rheumatoid arthritis: a review. Biomed. Pharmacother. 2006 Dec;60(10):648-55. 73. Misra UK, Gonzalez-Gronow M, Gawdi G, Pizzo SV. The role of MTJ-1in cell surface translocation of GRP78, 2 receptor for alpha2-macroglobulin-dependent signaling. J Immunol. 2005 Feb 15;174(4):2092-7. 74. Misra UK, Deedwania R, and Pizzo SV. Activation and cross-talk between Akt, NF-kappaB, and unfolded protein response signaling in 1-LN prostate cancer cells consequent to ligation of cell surface-associated GRP78. J. Biol. Chem. 2006 May 12;281(19):13694-707. 75. Nakae S, Nambu A, Sudo K, and Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 2003 Dec 1;171(11):6173-7. 76. Neumann E, Barnum SR, Tarner IH, Echols J, Fleck M, Judex M, Kullmann F, Mountz JD, Schölmerich J, Gay S, and Müller-Ladner U. (2002). Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum. 2002 Apr;46(4):934-45. 77. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, and Dijkmans BA. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004 Feb;50(2):380-6. 78. Nienhuis RL. and Mandema E. (1964). A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor. Ann. Rheum. Dis. 1964 Jul;23:302-5 79. Niewold TB, Harrison MJ, and Paget SA. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM. Apr;100(4):193-201. 80. Oliver JE, Worthington J, and Silman AJ. Genetic epidemiology of rheumatoid arthritis. Curr. Opin. Rheumatol. 2006 Mar;18(2):141-6. 81. Olsen NJ and Stein CM. (2004). New drugs for rheumatoid arthritis. N. Engl. J. Med. 2004 May 20;350(21):2167-79. 82. Person MD, Shen J, Traner A, Hensley SC, Lo HH, Abbruzzese JL, and Li D. Protein fragment domains identified using 2D gel electrophoresis/MALDI-TOF. J. Biomol. Tech. 2006 Apr;17(2):145-56. 83. Rogers GE. Occurrence of citrulline in proteins. Nature 1962 Jun 23;194:1149-51. 84. Rogers GE, Harding HW, and Llewellyn-Smith IJ. The origin of citrulline-containing proteins in the hair follicle and the chemical nature of trichohyalin, an intracellular precursor. Biochim. Biophys. Acta 1977 Nov 25;495(1):159-75. 85. Rønningen KS, Spurkland A, Egeland T, Iwe T, Munthe E, Vartdal F, and Thorsby E. Rheumatoid arthritis may be primarily associated with HLA-DR4 molecules sharing a particular sequence at residues 67-74. Tissue Antigens 1990 Nov;36(5):235-40. 86. Roudier J, Petersen J, Rhodes GH, Luka J and Carson DA. Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110. Proc. Natl Acad. Sci. USA.1989 Jul;86(13):5104–8. 87. Ruddy S and Austen KF. Activation of the complement and properdin systems in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1975 Jun 13;256:96-104. 88. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, and van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest 1998 Jan 1;101(1):273-81. 89. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, and van Venrooij WJ. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000 Jan;43(1):155-63. 90. Scott DL and Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. N. Engl. J. Med. 2006 Aug 17;355(7):704-12. 91. Senshu T, Sato T, Inoue T, Akiyama K, and Asaga H. Detection of citrulline residues in deiminated proteins on polyvinylidene difluoride membrane. Anal. Biochem. 1992 May 15;203(1):94-100. 92. Shin BK, Wang H, Yim AM, Le Naour F, Brichory F, Jang JH, Zhao R, Puravs E, Tra J, Michael CW, Misek DE, and Hanash SM. Global profiling of the cell surface proteome of cancer cells uncovers an abundance of proteins with chaperone function. J. Biol. Chem. 2003 Feb 28;278(9):7607-16. 93. Simmonds RE and Foxwell BM. Signalling, inflammation and arthritis: NF-kappaB and its relevance to arthritis and inflammation. Rheumatology. (Oxford) 2008 May;47(5):584-90. 94. Skapenko A, Leipe J, Lipsky PE, Schulze-Koops H. The role of the T cell in autoimmune inflammation. Arthritis Res Ther. 2005;7 Suppl 2:S4-14. 95. Smeets TJ, Dolhain RJEM, Miltenburg AM, de Kuiper R, Breedveld FC, and Tak PP. Poor expression of T cell-derived cytokines and activation and proliferation markers in early rheumatoid synovial tissue. Clin. Immunol. Immunopathol. 1998 Jul;88(1):84-90. 96. Srivastava P. Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol. 2002 Mar;2(3):185–94 97. Stamp LK, James MJ, and Cleland LG. Interleukin-17: the missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis? Immunol. Cell Biol. 2004 Feb;82(1):1-9. 98. Stastny P. Mixed lymphocyte cultures in rheumatoid arthritis. J. Clin. Invest 1976 May;57(5):1148-57. 99. Stastny P. HLA and the role of T cells in the predisposition to disease. Rheum. Dis. Clin. North Am. 1987 Apr;13(1):1-6. 100. Stensland ME, Pollmann S, Molberg Ø, Sollid LM, Fleckenstein B. Primary sequence, together with other factors, influence peptide deimination by peptidylarginine deiminase-4. Biol Chem. 2009 Feb;390(2):99-107 101. Suzuki A, Yamada R, Chang X, Tokuhiro S, Sawada T, Suzuki M, Nagasaki M, Nakayama-Hamada M, Kawaida R, Ono M, Ohtsuki M, Furukawa H, Yoshino S, Yukioka M, Tohma S, Matsubara T, Wakitani S, Teshima R, Nishioka Y, Sekine A, Iida A, Takahashi A, Tsunoda T, Nakamura Y, and Yamamoto K. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 2003 Aug;34(4):395-402. 102. Suzuki A, Yamada R, and Yamamoto K. Citrullination by peptidylarginine deiminase in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 2007 Jun;1108:323-39. 103. Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P, van der Heijde D, Landewé R, and Kvien TK. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann. Rheum. Dis. 2008 Feb;67(2):212-7. 104. Trouw LA, Haisma EM, Levarht EW, van der Woude D, Ioan-Facsinay A, Daha MR, Huizinga TW, and Toes RE. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum. 2009 Jul;60(7):1923-31. 105. Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, and Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006 Jul 1;108(1):253-61. 106. van der Heide A., Jacobs,J.W., Bijlsma,J.W., Heurkens,A.H., van Booma-Frankfort,C., van,d., V, Haanen,H.C., Hofman,D.M., van Albada-Kuipers,G.A., ter Borg,E.J., Brus,H.L., Dinant,H.J., Kruize,A.A., and Schenk,Y. (1996). The effectiveness of early treatment with 'second-line' antirheumatic drugs. A randomized, controlled trial. Ann. Intern. Med. 124, 699-707. 107. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, Toes RE, and Huizinga TW. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004a Mar;50(3): 709-15. 108. van Gaalen FA, van Aken J, Huizinga TW, Schreuder GM, Breedveld FC, Zanelli E, van Venrooij WJ, Verweij CL, Toes RE, and de Vries RR. (2004b). Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum. 2004b Jul;50(7):2113-21. 109. Vossenaar ER, Radstake TR, van der Heijden A, van Mansum MA, Dieteren C, de Rooij DJ, Barrera P, Zendman AJ, and van Venrooij WJ. (2004a). Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann. Rheum. Dis. 2004a Apr;63(4):373-81. 110. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, van Venrooij WJ, and Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum. 2004b Nov;50(11):3485-94. 111. Vossenaar ER, Zendman AJ, van Venrooij WJ, and Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003 Nov;25(11):1106-18. 112. Walser-Kuntz DR, Weyand CM, Fulbright JW, Moore SB & Goronzy JJ. HLA-DRB1 molecules and antigenic experience shape the repertoire of CD4 T cells. Hum. Immunol. 1995 Dec;44(4):203–9. 113. Wang Y, Wysocka J, Sayegh J, Lee YH, Perlin JR, Leonelli L, Sonbuchner LS, McDonald CH, Cook RG, Dou Y, Roeder RG, Clarke S, Stallcup MR, Allis CD, and Coonrod SA. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science 2004 Oct;306(5694):279-83. 114. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999 Jan;340(4):253–9. 115. Weyand CM and Goronzy JJ. Pathomechanisms in rheumatoid arthritis--time for a string theory? J. Clin. Invest 2006 Apr;116(4):869-71. 116. Wordsworth BP, Lanchbury JS, Sakkas LI, Welsh KI, Panayi GS, and Bell JI. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc. Natl. Acad. Sci. U. S. A 1989 Dec;86(24),10049-53. 117. Yamada R. Peptidylarginine deiminase type 4, anticitrullinated peptide antibodies, and rheumatoid arthritis. Autoimmun. Rev. 2005 Apr;4(4):201-6. 118. Yamasaki S, Kawakami A, Nakashima T, Nakamura H, Kamachi M, Honda S, Hirai Y, Hida A, Ida H, Migita K, Kawabe Y, Koji T, Furuichi I, Aoyagi T, Eguchi K. Importance of NF-kappaB in rheumatoid synovial tissues: in situ NF-kappaB expression and in vitro study using cultured synovial cells. Ann Rheum Dis 2001 Jul;60(7):678–84. 119. Young BJ, Mallya RK, Leslie RD, Clark CJ, and Hamblin TJ. Anti-keratin antibodies in rheumatoid arthritis. Br. Med. J. 1979 Jul 14;2(6182):97-9. 120. Young CL, Feierstein A, and Southwick FS. (1994). Calcium regulation of actin filament capping and monomer binding by macrophage capping protein. J. Biol. Chem. 1994 May 13;269(19):13997-4002. 121. Zanelli E, Breedveld FC and de Vries RR. HLA association with autoimmune disease: a failure to protect? Rheumatology 2000 Oct;39(10):1060–6. 122. Zvaifler NJ. The immunopathology of joint inflammation in rheumatoid arthritis. Adv. Immunol. 1973;16(0):265336. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/8666 | - |
dc.description.abstract | 類風濕性關節炎是免疫風濕科領域相當重要的疾病,主要以慢性對稱性多關節炎為其表現,約佔總人口的1%。關節持續的發炎腫脹,常常會造成患者關節變型,甚至導致患者的死亡率上升。雖然之前已經有相當多的研究來探討其致病機轉,但是對於真正引起關節慢性發炎的分子機轉仍然不清楚。近年來,抗瓜氨酸化胜肽抗體(anti-citrullinated peptide antibodies; ACPAs)的發現為新的里程碑。它可以非常專一的出現在類風濕性關節炎的血清中,尤其是在疾病表徵尚未產生之前就已經出現了。而且患者血清中抗瓜氨酸化胜肽抗體的效價和其疾病活動性密切相關。直到目前學界的研究結論認為,抗瓜氨酸化胜肽抗體在類風濕關節炎的致病機轉中,扮演重要的角色。然而確切的分子機轉仍然沒有合理的解釋。在本研究中分為臨床及基礎研究兩部分,首先在臨床方面,我們比較抗瓜氨酸化胜肽抗體,類風濕因子及抗無乳酸免疫球蛋白抗體在台灣臨床上鑑別診斷類風濕性關節炎及其相仿者的優劣。在基礎方面,我們假設單核白血球細胞表面上有自體抗原可以被抗瓜氨酸化胜肽抗體所認識。而抗瓜氨酸化胜肽抗體可以藉由結合這些細胞表面分子直接引起發炎反應。
在實驗方法上,首先收集類風濕性關節炎,原發性修格連氏症,慢性B型肝炎,慢性C型肝炎及健康志願者的血清,以濁度分析法偵測類風濕因子,以酵素免疫分析法偵測無乳酸免疫球蛋白抗體和抗瓜氨酸化胜肽抗體,並比較其在鑑別診斷類風濕性關節炎及其相仿者的敏感度及特異度。之後取ACPAs(+)類風濕性關節炎患者的血清利用親合性管柱結合環狀瓜氨酸化胜肽,純化出抗瓜氨酸化胜肽抗體。接著和健康人的單核性白血球或細胞株U937一起培養。以酵素免疫分析法偵測TNF-α的釋放及轉錄因子NF-κB的活化。再來以ACPAs當偵測抗體,利用西方點墨法找出作用的自體抗原,最後取出並送蛋白質鑑定。 在臨床上的研究結果顯示,在抗瓜氨酸化胜肽抗體、類風濕因子及抗無乳酸免疫球蛋白抗體之中,抗瓜氨酸化胜肽抗體對於鑑別診斷類風濕性關節炎及其相仿者的敏感度及特異度最高。在基礎研究方面,以親合性管柱純化出的抗瓜氨酸化胜肽抗體和U937細胞共同培養,可以促進TNF-α的釋放及轉錄因子NF-κB的活化。相對的,以去除掉抗瓜氨酸化胜肽抗體的類風濕關節炎患者血清,則無此作用。我們分離出U937細胞膜上的蛋白質,以抗瓜氨酸化胜肽抗體為第一抗體,用西方點墨法發現抗瓜氨酸化胜肽抗體可以和膜上的蛋白質結合,最後以蛋白質體學的方法,證實glucose-regulated protein of 78 kDa (GRP78)為其對應抗原。我們並發現,以基因合成的GRP78並不會跟抗瓜氨酸化胜肽抗體結合,但是從U937細胞所分離出來的膜蛋白,再以免疫沉澱法純化的GRP78則可以,乃因U937細胞膜上GRP78的有瓜氨酸化的現象,而基因合成的GRP78則沒有。將基因合成的GRP78給予瓜氨酸化後,可以和抗瓜氨酸化胜肽抗體結合,並且抑制抗瓜氨酸化胜肽抗體引起的U937細胞TNF-α釋放。最後我們驗證,健康人血液中的單核性白血球上有GRP78的表現,而且抗瓜氨酸化胜肽抗體也可以促進其TNF-α釋放。 本研究的結論是,抗瓜氨酸化胜肽抗體不單只是一個相當有用的類風濕性關節炎診斷上的血清學指標,其更可以藉由直接結合在細胞膜上瓜氨酸化的GRP78,促進單核性白血球轉錄因子NF-κB的活化及TNF-α的釋放,引起發炎反應。我們的實驗證實了ACPAs直接參與了類風濕性關節炎的免疫病理機轉。 | zh_TW |
dc.description.abstract | Rheumatoid arthritis (RA) is an important disease in rheumatology and its prevalence rate is around 1%. It is characterized by chronic symmetric polyarticular synovitis. Persistent joint swelling and inflammation not only caused the deformity of joints but also increased the mortality in RA patients. Althouth there were many studies investigating the pathogenesis of RA, the definite molecular mechanism of chronic synovitis remained to be elucidated. In recent years, the discovery of anti-citrullinated peptide antibodies (ACPAs) was a milestone in RA. Currently ACPAs was the most specific marker autoantibody in RA patients correlating with its disease activity. In addition, the most unique nature of ACPAs is that the autoantibody may appear even before the onset of arthritis. It is conceivable that ACPAs were involved in the pathogenesis of RA; however the definite molecular pathogenesis has not been elucidated. My thesis contains both clinical and basic dimension about ACPAs in the pathogenesis of RA. In clinical setting, we evaluated the usefulness of anti-agalactosyl IgG antibodies〔anti-Gal(0) IgG〕, rheumatoid factors (RF) and ACPAs in the differential diagnosis of different rheumatic disorders mimicking RA. In basic research, we hypothesized that ACPAs may directly bind to cell surface citrullinated proteins to stimulate mononuclear cells to elicite inflammatory reaction.
ACPAs were purified from pooled ACPAs (+) RA sera by cyclic citrullinated peptide (CCP)-conjugated affinity column. After co-culture of U937 cells with ACPAs, the tumor necrosis factor (TNF)-α production and nuclear factor (NF)-κB DNA binding activity of the cells were measured by ELISA. The cognate antigen(s) of ACPAs on the U937 cell surface was probed by ACPAs, and the reactive bands were identified by proteomic analysis. In clinical setting, ACPAs was the most specific and sensitive biomarker for diagnosis of RA from its mimic. In basic research, ACPAs specifically enhanced TNF-α production and increased DNA binding activity of NF-κB in U937 cells. In contrast, ACPA-depleted RA sera failed to activate U937 cells. Proteomic analysis revealed that glucose-regulated protein 78 (GRP78, 72 kDa) was one of the cognate antigens for ACPAs. GST-tagged recombinant GRP78 could not recognize by ACPAs due to lack of citrullination. In addition, we found that GRP78 was citrullinated on U937 cell surface that rendered its binding activity with ACPAs. The citrullinated GRP78 inhibited ACPA-induced TNF-α production by U937. ACPAs also bound to human monocytes to promote TNF-α production. In conclusion, the presence of ACPAs was a very useful biomarker for diagnosis of RA. Furthermore, we clearly demonstrated that ACPAs enhanced the NF-κB activity and TNF-α production in monocytes/macrophages via binding to surface-expressed citrullinated GRP78 that involved in rheumatoid pathogenesis. | en |
dc.description.provenance | Made available in DSpace on 2021-05-20T19:59:30Z (GMT). No. of bitstreams: 1 ntu-99-Q93421008-1.pdf: 2524266 bytes, checksum: d33129bc981db564faa5bab1351463fd (MD5) Previous issue date: 2010 | en |
dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii 英文摘要 v 博士論文內容 第一章 緒論 1 第一節 類風濕性關節炎 3 第二節 現有類風濕性關節炎的致病機轉 6 第三節 T細胞在類風濕關節炎所扮演的角色 7 第四節Cytokine Network在類風濕關節炎所扮演的角色 9 第五節B細胞及自體抗體在類風濕關節炎所扮演的角色 11 第六節 抗瓜氨酸化胜肽抗體 13 第七節 胜肽化精氨酸去氨脢 14 第八節 抗瓜氨酸化胜肽抗體之於類風濕性關節炎 18 第九節 葡萄糖調節蛋白質78之於類風濕性關節炎 24 第十節 研究的假說及特定目的 26 第二章 研究方法與材料 27 第三章 結果 第一部份 抗瓜氨酸化胜肽抗體專一的存在類風濕性關節炎血清中 40 第二部分 抗瓜氨酸化胜肽抗體促進人類單核球產生發炎反應 41 第三部分 尋找抗瓜氨酸化胜肽抗體促進發炎反應的作用分子 43 第四部分 GRP78是抗瓜氨酸化胜肽抗體產生發炎反應的關鍵分子 46 第四章 討論 第一部分 抗瓜氨酸化胜肽抗體專一的存在類風濕性關節炎血清中 50 第二部分 抗瓜氨酸化胜肽抗體促進人類單核球產生發炎反應 51 第三部分 尋找抗瓜氨酸化胜肽抗體促進發炎反應的作用分子 58 第四部分 GRP78是抗瓜氨酸化胜肽抗體產生發炎反應的關鍵分子 64 第五章 展望 第一節 類風濕性關節炎目前治療的困境 73 第二節 本研究對於類風濕性關節炎臨床診斷及治療的影響 75 第三節 本研究對類風濕性關節炎基礎研究的影響 77 第四節 未來的研究規劃 81 第五節 結論 83 第六章 論文英文簡述 84 第七章 參考文獻 108 | |
dc.language.iso | zh-TW | |
dc.title | 抗瓜氨酸化胜肽抗體在類風濕性關節炎免疫病理致病機轉上所扮演的角色 | zh_TW |
dc.title | Study on the Molecular Basis of Anti-Citrullinated Peptide Antibodies in the Immunopathogenesis of Rheumatoid Arthritis | en |
dc.type | Thesis | |
dc.date.schoolyear | 98-2 | |
dc.description.degree | 博士 | |
dc.contributor.coadvisor | 蔡嘉哲 | |
dc.contributor.oralexamcommittee | 蔡長祐,孫光蕙,賴振宏,楊偉勛,鄭文芳 | |
dc.subject.keyword | 類風濕性關節炎,抗瓜氨酸化胜肽,抗體,抗腫瘤壞死因子,單核性白血球,葡萄糖調節蛋白質78, | zh_TW |
dc.subject.keyword | rheumatoid arthritis,anti-citrullinated peptide antibodies,tumor necrosis factor-α,monocytes,glucose-regulated protein 78, | en |
dc.relation.page | 160 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2010-06-07 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-99-1.pdf | 2.47 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。